Partnerships & Collaborations

At Crystec we pride ourselves on our relationships with our collaborators, partners and clients, without whom we would not be the company that we are today. Below are a selection of the organisations and individuals who support our business and research activities, and play a key role in helping us to transform the performance of medicines.

Strategic Research Collaborations

University of Bradford

Crystec’s Alma Mater, from which Bradford Particle Design was originally spun out. The University of Bradford continue to work with Crystec in a number of ways including providing access to facilities, as well as support with student internships and projects.

University of Leeds

The University of Leeds are working with Crystec to develop new bioprocessing techniques with a view to creating more active, stable and more readily reconstituted biotherapeutics. In addition, Crystec and the University of Leeds are collaborating on a new therapeutic for the treatment of stroke.

Tsinghua University

One of China’s leading universities, Tsinghua are working with Crystec on the modernisation of Traditional Chinese Medicines (TCMs). We are working together to develop a mechanistic understanding of the function of TCMs, to purify where needed, to standardise their composition, and improve their performance, in order to create opportunities for Chinese medicines to be more successfully adopted in markets worldwide.

University of Paris-sud. Institut des Sciences Moléculaires d'Orsay

One of France’s most prestigious institutes, the CNRS Institut des Sciences Moléculaires d’Orsay is working with Crystec on the development of novel nanoscale delivery systems.

Shanghai Institute of Materia Medica (SIMM)

Part of the prestigious Chinese Academy of Sciences organisation, SIMM operate as our pharmaceutical solid state and formulation research partner in China. SIMM is the oldest research institution for drug discovery and development in China and is recognized worldwide for its outstanding research, including a Nobel Prize for work on the malaria medicine, artemisinin. Partnerships with Crystec include co-development of a more bioavailable and stable version of this artemisinin. SIMM are also Crystec’s principal partner in China on the Newton Research and Innovation Bridges programme, co-developing a next generation inhaled medicine for the treatment of respiratory disease in China.

Development Platforms

Advanced Manufacturing Supply Chain Initiative (AMSCI), Project ReMediES

The AMSCI programme was established to improve the global competitiveness of UK advanced manufacturing supply chains. The ReMediES (RE-configuring MEDIcines End-to-end Supply) project is building a more patient-centric and integrated end-to-end supply chain as part of a sector-wide, initiative. ReMediES is evaluating the benefits of new disruptive technology innovations (including mSAS®) within the UK pharmaceutical supply chain.

UK - China Innovation Bridges Newton Fund Project

Crystec have been awarded a grant from the Newton Fund (InnovateUK and MoST China) to tackle the increasing burden of chronic obstructive pulmonary disease (COPD) in China. We are working collaboratively with Dr Omar Usmani at Imperial College London, Royal Brompton Hospital, an international authority on aerosol science and respiratory medicine. We are also working with partners based in China, such as Professor Jiwen Zhang, a senior scientist at the Shanghai Institute of Materia Medica (SIMM). A joint Venture has been established with a leading Chinese pharmaceutical company to support the development and commercialisation of a novel treatment for COPD.

Specialist Partnerships

Cormica Bradford

Cormica Bradford amalgamates the expertise from several leading science-based CROs to create a fully integrated, highly competent partner for life science research and development services, equipped with a diverse range of expertise and state of the art equipment, serving a global client base. Their analytical division provide high quality analytical support to companies across a wide range of industries, and are distinguished by a wide range of techniques. They are able to support work from initial Method Development, through to final cGMP Product Release.

Woodley BioReg (WBR)

WBR are Crystec’s quality and regulatory consultants. They help companies in the bio/pharmaceutical, medical and health industries to develop and manufacture quality products that are effective and safe for patients worldwide. They provide scientific advice and consulting services in Regulatory Affairs, Quality Assurance (cGMP), and Project Management for all stages of product development, acting as the link between the global Boards of Health/Regulatory Agencies and product developers.